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STUDY PROTOCOL Open Access
Comparing the effectiveness of the 0.018-inch
versus the 0.022-inch bracket slot system in
orthodontic treatment: study protocol for a
randomized controlled trial
Ahmed MF El-Angbawi*, David R Bearn and Grant T McIntyre
Abstract
Background: Edgewise fixed orthodontic appliances are available in two different bracket slot sizes (0.018 and
0.022 inch). Both systems are used by clinicians worldwide with some orthodontists claiming the superiority and
clinical advantages of one system over the other. However, the scientific evidence supporting this area is scarce
and weak. This leaves the clinician’s choice of bracket slot system to clinical preference. We aim to compare the
0.018-inch and 0.022-inch pre-adjusted bracket slot systems in terms of the effectiveness of orthodontic treatment.
Methods/Design: This is a prospective, multicenter, randomized clinical trial, undertaken in the secondary care
hospital environment in the NHS Tayside region of Scotland (United Kingdom). A total of 216 orthodontic patients will
be recruited in three centers in secondary care hospitals in NHS Tayside. The participants will be randomly allocated to
treatment with either the 0.018-inch or 0.022-inch bracket slot systems (n = 108 for each group) using Victory series™
conventional pre-adjusted bracket systems (3 M Unitek, Monrovia, United States). Baseline records and outcome data
collected during and at the end of orthodontic treatment will be assessed. The primary outcome measures will be the
duration of orthodontic treatment in the maxillary and mandibular arches. The secondary outcome measures will be
the number of scheduled appointments for orthodontic treatment in the maxillary and mandibular arches, treatment
outcome using Peer Assessment Rating index (PAR), orthodontically induced inflammatory root resorption (as measured
using periapical radiographs) and the patient’s perception of wearing orthodontic appliances.
Discussion: The results from the current study will serve as evidence to guide the clinician in deciding whether the
difference in bracket slot size has a significant impact on the effectiveness of orthodontic treatment.
Trial registration: Registered with ClinicalTrials.gov on 5 March 2014, registration number: NCT02080338.
Keywords: Orthodontic treatment, Bracket slot size, Effectiveness, Randomized clinical trial, Clinical outcomes,
Duration of treatment
Background
Malocclusion is a common worldwide dental problem,
often causing aesthetic and functional concerns, which
can lead to a negative impact on the quality of life [1,2].
Malocclusion is normally corrected using orthodontic
treatment which includes fixed and/or removable braces.
There are a number of fixed appliance systems used in
contemporary orthodontics which include multiple pre-
adjusted edgewise fixed appliance systems. Edward H
Angle is regarded as the father of modern orthodontics
and introduced the ‘edgewise’ bracket into orthodontic
treatment in 1925 as a development of the ‘ribbon arch’
appliance. The interaction between the edgewise bracket
slot and the orthodontic archwire can determine the na-
ture of the orthodontic forces. In order that the gold
archwires were sufficiently rigid, Angle proposed the
bracket slot dimensions be 0.022 by 0.028 inches. The
advent of stainless steel alloys facilitated the use of
smaller dimension wires with the same rigidity as that of
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the larger gold alloy archwires. This allowed the bracket
slot size to be reduced, and as a result the 0.018-inch
bracket slot was introduced into orthodontics. However,
the introduction of the 0.018-inch bracket slot did not
eliminate fixed appliance systems using 0.022-inch bracket
slots from clinical practice [3].
In the last 20 years, a number of other alloy archwires
have been developed. These include standard nickel ti-
tanium, thermally activated nickel titanium, superelastic
nickel titanium and titanium-molybdenum archwires.
Despite these advances in metallurgy, no high quality
studies have sought to investigate the effectiveness of
0.018-inch compared with 0.022-inch bracket slots in
orthodontic treatment. Only two retrospective studies
have compared the duration of treatment for patients
treated with 0.018-inch slot and 0.022-inch slot fixed ap-
pliance systems [4,5]. It is interesting to note that these
two studies reported a statistically significant reduction
in the mean orthodontic treatment duration for the
0.018-inch slot system; however, this difference was not
considered by the authors to be clinically significant.
A number of biomechanical advantages and disadvan-
tages have been suggested for both 0.018-inch and
0.022-inch bracket slots. It has been postulated that
overbite reduction (a key stage in fixed appliance ortho-
dontic treatment) and closure of any residual extraction
space may be more efficient with 0.022-inch bracket
slots as the space between the working archwire (0.019
by 0.025-inch stainless steel) and the 0.022-inch bracket
slot (known as slop) allows exaggerated bite-opening
bends to be placed whilst still being able to be fitted with
relative ease [6]. Conversely, the working archwire (0.016
by 0.022-inch stainless steel) for 0.018-inch bracket slots is
presumed to deliver third order movement (known as
torque) more effectively and earlier in treatment without
additional wire bending [6].
All fixed appliance orthodontic treatment results in
adverse effects on the roots of the teeth, the most com-
mon being orthodontically induced inflammatory root
resorption (OIIRR). Excessive forces during treatment
have been associated with iatrogenic damage including
OIIRR, periodontal destruction, loss of crestal bone
height and loss of pulp vitality. It is not known if these
are actually significantly reduced when 0.018-inch bracket
slots are used, although different appliances are associated
with differing levels of biological trauma during treatment
[7]. A retrospective study by Sameshima and Sinclair [8]
which investigated multiple treatment factors for the pre-
diction and prevention of OIIRR reported that difference
in bracket slot size was not significantly associated with
OIIRR.
The preference for each slot size varies throughout the
world. In the United Kingdom, the majority of orthodon-
tists continue to use 0.022-inch bracket slots. However, in
the rest of mainland Europe, 0.018-inch bracket slots are
more commonly used, whilst in the United States, the ma-
jority of orthodontists work with 0.022-inch bracket slots.
It has been estimated that approximately 10% of Americans
relocate to another state each year and this is likely to also
be true for Europe and the United Kingdom [9]. When pa-
tients undergoing orthodontic treatment transfer to a dif-
ferent orthodontist, the dichotomy in orthodontic bracket
sizes is not only inconvenient for the new orthodontist if
appropriate inventory is not kept in stock, but unnecessary
potential side-effects can occur if active treatment is pro-
longed. These biological and clinical management prob-
lems could all be avoided or minimized if one slot size was
shown to be superior and subsequently adopted by the
profession as the international standard [3,9].
The aim of this trial is to provide reliable evidence for
clinicians as to whether the use of 0.018-inch or 0.022-
inch bracket slot systems has any impact on the effect-
iveness of orthodontic treatment. We will do this by
determining if the use of 0.018-inch and 0.022-inch
bracket slot systems has any effect on the duration or
quality of result of orthodontic treatment, patient’s per-
ception of treatment or the biological side effects associ-
ated with orthodontic treatment. We hypothesize that
there is no difference in the outcomes of orthodontic
treatment (as listed above) using either a 0.018-inch or
0.022-inch slot fixed appliance system.
Methods/Design
Trial design
The current trial is a multicenter, two-arm, parallel group,
randomized controlled trial (Figure 1) designed following
the CONSORT guidelines [10]. Patients who give in-
formed consent to participate in this study will be entered
into the study database, which will be held on one of the
computers within the Orthodontic Department at Dundee
Dental Hospital and School. Each participating patient will
be allocated the next available study number at the start of
active treatment using a series of opaque envelopes con-
taining the treatment group.
This trial will recruit orthodontic patients from three
sites in secondary care setting in NHS Tayside, Scotland:
Dundee Dental Hospital and School, Perth Royal Infirm-
ary and Springfield Medical Centre (Arbroath). Prior to
study recruitment at any individual site, there will be a
site initiation visit and site staff will receive training on
the study design, methodology, clinical intervention and
maintaining trial documentation, including the case re-
port forms questionnaires and investigator site file.
Participant inclusion criteria
Patients scheduled to undergo dual arch fixed appliance
orthodontic treatment in any of the three trial centers
will be invited to participate in this trial by the operator
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planning to conduct their orthodontic treatment. Pa-
tients who are eligible to receive treatment in the NHS
Scotland should have a significant need of treatment
which requires an Index of Orthodontic Treatment Need
(IOTN) score of 4 or 5 for the dental health component,
or a score of 3 combined with a high aesthetic compo-
nent score (>5) [11]. All types of malocclusions (Class I,
II and III malocclusions) will be recruited to the study in-
cluding cases which require extraction or non-extraction
as part of the treatment plan.
Participant exclusion criteria
Participants will be excluded if they fulfil any of the fol-
lowing criteria: patients who have undergone previous
orthodontic treatment including fixed, removable and
functional appliances; patients less than 12-years-old at
the start of orthodontic treatment; patients with orofacial
clefting, severe hypodontia and special needs patients; and
patients undergoing orthognathic (jaw) surgery as part of
their orthodontic treatment plan.
Intervention protocol
All teeth will undergo pumice and water prophylaxis im-
mediately before bonding and banding. The teeth will
then be prepared using self-etching primer (Transbond™
Plus Self Etching Primer, 3 M Unitek, Monrovia, United
States). Depending on the card inside the participant’s
envelope, either 0.018-inch or 0.022-inch slot Victory
Series™ McLaughlin, Bennett, Terevisi (MBT) prescription
adhesive pre-coated (APC) brackets and buccal tubes (or
bands, where appropriate) (APC™ II Victory Series Twin
MBT™, 3 M Unitek, Monrovia, United States] will be
Figure 1 Trial CONSORT flow chart with projected numbers of participants throughout the trial. Intervention 1: 0.018-inch bracket slot
system and intervention 2: 0.022-inch bracket slot system.
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placed. A standardized wire sequence for each bracket slot
system will be followed whenever clinically appropriate.
The 0.018-inch bracket slot system archwire sequence will
be: 0.016-inch nickel titanium alloy archwire, followed by
0.016 × 0.022-inch nickel titanium alloy archwire followed
by 0.016 × 0.022-inch stainless steel archwire. The 0.022-
inch bracket slot system sequence will be: 0.016-inch
nickel titanium alloy archwire, followed by 0.019 × 0.025-
nickel titanium alloy archwire followed by 0.019 × 0.025-
inch stainless steel archwire.
A flow chart for the study (Figure 2) showing the key
steps will be attached to the participant’s clinical case
notes to help remind clinicians to adhere to study proto-
col. A standardized clinical treatment regime will be
Figure 2 Trial key steps diagram. Showing the pre-treatment, mid-treatment and end of treatment records collected. Smile better questionnaire is
completed by the study participants with regards to their experience wearing the fixed appliances. Index of Orthodontic Treatment Need Aesthetic
Component (IOTN AC), Orthopantomograph (OPT).
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used throughout the trial, accepting that clinical circum-
stances may necessitate deviations from the standard
protocol.
Outcome measures
At the end of the trial, the standardized records will be
anonymized before any scoring will be undertaken. Thus
the investigator will be blind to the allocation before any
observations are recorded in order to eliminate investi-
gator bias.
Primary outcome
The primary outcome will be the duration of orthodon-
tic treatment (measured in months) required to finish
orthodontic treatment in both the maxillary and man-
dibular arches, including the number of visits required
to complete treatment.
Secondary outcomes
The first secondary outcome will be the treatment out-
come. This will be measured by evaluating the quality of
treatment, the effectiveness of the appliance in delivering
torque and the improvement in dental attractiveness.
The quality of the treatment result will principally be
measured by assessing the occlusal outcome using the
Peer Assessment Rating Index (PAR Index) from study
models recorded at the start and end of treatment. The
torque of the maxillary incisors will be used to evaluate
the effectiveness of appliance in delivering effective
torque by measuring the angle between the long axis of
the central incisors and the maxillary base from lateral
cephalograms towards the end of treatment. The im-
provement in the dental attractiveness of the patient will
be calculated using the aesthetic component of the
IOTN. This will be evaluated by comparing the patient
rating to the attractiveness of his or her teeth before and
after treatment.
The second secondary outcome will be the biological
side effects of the treatment, as measured by the amount
of OIIRR. OIIRR will be established from periapical ra-
diographs recorded at nine months into active treat-
ment. Patients who show evidence of marked OIIRR will
be treated in accordance with current recommendations.
The third secondary outcome will be the patient’s per-
ception of wearing the fixed orthodontic appliance and
of treatment outcome. This will be recorded using a
questionnaire (Smiles Better) at six months after the start
of treatment. Patient perception of the of fixed appliance
treatment outcome will be measured by comparing pa-
tients’ pre-treatment and after-treatment questionnaires.
Target sample size
The sample size calculation is based on the primary out-
come of duration of orthodontic treatment. Using nQuery
Advisor 7.0 sample size was calculated to detect a differ-
ence in mean treatment duration of three months (clinically
important difference). Standard deviation was estimated
using the studies of Amditis and Smith [5] and Eberting
et al. [12]. A sample size of 92 in each group will have
80% power to detect a difference in means of three
months assuming that the common standard deviation
is 7.2 using a two group Student’s t-test with a 0.05
two-sided significance level. Assuming a 15 to 20%
dropout rate, we will recruit a total of 216 patients.
Participant recruitment
Patients attending the orthodontic department in any of
the trial centers for orthodontic treatment who meet the
inclusion criteria will be assessed by the clinician plan-
ning the orthodontic treatment. The patients will be in-
vited to participate in the study and will be given a
participant’s and/or parents’ information sheet to take
home with them. Patients will be asked to decide about
joining the trial on the next appointment (after at least
two weeks).
Sequence generation and randomization
Simple randomization will be accomplished with no strati-
fication using a restricted (10 number block) random
number using www.graphpad.com/quickcalcs/randomn2.
cfm to ensure equivalence of numbers in each group. The
odd numbers will be allocated to group 1 and the even
numbers to group 2. In every 10 number block from the
random table, the sequence will be checked to ensure the
even numbers are equal to the odd numbers. Each num-
ber in the random table will be given a study number and
assigned into one of the study groups. A table for the allo-
cation of the participants in the study will be composed
and kept in a sealed envelope. All the documents used for
the randomization and allocation sequence generation will
be kept in a box in a locked office away from the clinical
environments.
Participant allocation
Numbered, identical, opaque sealed envelopes will be
used for patient allocation in the current trial. The allo-
cation envelope contains the treatment allocation card
showing either group 1 or group 2. The allocation enve-
lopes will be kept in a labelled box in an agreed location
in the clinical environments. After the clinician obtains
informed consent from the patient, a dental nurse will
be asked to identify the next allocation envelope in se-
quence. The allocation will only be revealed at the time
of appliance placement. Then the allocation envelope
will be opened in front of the participant. Both the par-
ticipant and the clinician will be informed about the
group allocation for the participant.
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Blinding
Due to the nature of the trial it is not possible to blind
the clinician to the group once it is allocated. Once the
opaque numbered envelope used for random allocation
is opened and the clinician and participant know which
appliance type (either 0.018-inch slot or 0.022-inch slot)
will be used, the appliance will be clearly specified on
the pro forma kept within the patient’s case notes. This
will allow the clinician to adhere to the recommended
standard archwire sequence for each type of appliance.
Data and records to be collected
The following standardized data will be recorded for the
trial participants at three stages of orthodontic treat-
ment. Before start of orthodontic treatment: full ortho-
dontic diagnostic clinical assessment, orthodontically
trimmed study models at the start of orthodontic treat-
ment, IOTN (aesthetic component score), long-cone
paralleling technique periapical radiographs of maxillary
central incisors, lateral cephalometric radiographs re-
corded before the start of treatment and patient ques-
tionnaire (pre-treatment). During orthodontic treatment:
treatment duration, number of appointments, dates of key
stages in fixed appliance orthodontic treatment, number
of fixed appliance components replaced during active
treatment, patient questionnaires (Smiles Better) regard-
ing their perception of the impact of treatment (completed
by the patient at six months from the start of orthodontic
treatment), long-cone paralleling technique periapical
radiographs of maxillary incisors recorded at nine
months after the start of orthodontic treatment using
digital radiography and lateral cephalometric radiograph
recorded before the completion of active treatment.
End of orthodontic treatment: orthodontically trimmed
study models at the end of treatment, patient questionnaire
(post-treatment) and IOTN (aesthetic component score).
Data management
A data collection sheet designed specifically for the
current trial will be used to collect data from all partici-
pants’ records including study models, patient question-
naires, case notes and radiographs. The data collection
sheet will be coded to allow for the blinding of the
investigator to the type of appliance used during data
analysis. The data will then be uploaded into a validated
excel sheet specially designed for the current trial com-
plying with Good Clinical Practice regulations. At the
end of the trial the data will be exported into SPSS (Stat-
istical Package for Social Sciences, Inc., Chicago, Illinois,
United States) v.18 for statistical analysis.
Post-trial care
All study documentation will be retained for at least five
years post final data lock. The end of study is defined as
the last participant’s last visit. The end of the study will
be reported to the Research Ethics Committee (REC)
within 90 days, or 15 days if the study is terminated pre-
maturely. A summary report of the study will be pro-
vided to the REC within one year of the end of the
study.
Statistical analysis plan (SAP)
Descriptive statistics
Descriptive statistics for demographic data (such as age
and gender) and baseline measurements will be tabu-
lated by treatment group. Data will be checked for nor-
mality of distribution and any evidence of skewness.
Statistical analysis
Table 1 shows the planned statistical tests to be used for
each variable investigated. The significance level will be
set to α = 0.05 (two-tailed).
Intention-to-treat and imputation
Participants will be considered part of the intention-to-
treat population if they were randomized at the start of
the trial. If a participant has missing data for the out-
come, then the median value for the treatment group
will be imputed. To provide evidence of the robustness
of the study results obtained from the above analyses,
the same analyses will be repeated on two other data
sets; one where imputation is done using the 75th per-
centile instead of the median, and another using the
25th percentile. These three sets of results will then be
compared.
Table 1 Statistical tests
Outcome measure Type of variable Statistical test P <0.05
Primary outcome Duration of alignment stage for the
upper and lower arches
Continuous, assuming normal distribution One-way ANOVA test
Secondary outcomes Number of visits required Continuous, assuming normal distribution One-way ANOVA test
Occlusal outcome PAR Continuous, assuming normal distribution One-way ANOVA test
Patient perception Categorical data Chi-square test
Severity of OIIRR Categorical data Chi-square test or Friedman test
A list of statistical tests that will be used for data analysis depending on the type of data in the current trial. Peer Assessment Rating index (PAR), orthodontically
induced inflammatory root resorption (OIIRR), analysis of variance (ANOVA).
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Stopping rule
During the nine-month periapical radiographic assess-
ment, if severe OIIRR (more than one third of the root
Malmgren et al. [13]) is found in the majority of patients
in one group, whilst the other group shows minor
changes, then a trial monitoring committee will be con-
vened to consider whether the study will be terminated.
Operator standardization
All patients will be treated in the Dundee Dental Hospital,
Perth Royal Infirmary or Springfield Medical Center
(Arbroath) by specialist orthodontic staff. Patients will
be treated according to the study protocol. No additional
appointments will be required due to participation in the
study.
Trial monitoring
The Tayside Medical Science Centre standard operating
procedure on adverse event recording will be adhered to
for reporting of harms in the current study. Any partici-
pant reporting an adverse event would discuss this with
the clinic staff or may contact the trial team directly. All
adverse events will be recorded from the time partici-
pants have the orthodontic appliance bonded until the
date of debonding (end of treatment with appliance re-
moval). The trial is considered to be low risk and no ad-
verse events are expected from the fixed orthodontic
appliances that are used commonly and safely in most
orthodontic units around the world.
Trial Monitoring Committee
A Trial Monitoring Committee will be established, com-
posed of three researchers (DB, GM and AE). This commit-
tee will meet every three months to monitor and discuss
data for this trial. If it is found that one intervention par-
ticularly is causing significant harm to the dentition then
the committee will have to decide to terminate the trial and
shift all the study participants to the other intervention.
Investigator responsibilities
The principal investigators are responsible for the overall
conduct of the study at their site and compliance with
the protocol and any protocol amendments. Responsibil-
ities may be delegated to an appropriate member of
study site staff, which in this case is a senior clinical den-
tal staff member who has been nominated as a co-
investigator. Delegated tasks must be documented on a
delegation log and signed by all those named on the list.
Emergency code-breaking procedure
Emergency code-breaking in this randomized control trial
is not applicable because the bracket slot size system used
for each participant will be clearly detailed within the pa-
tient’s clinical notes. The proposed intervention is unlikely
to result in significant adverse events. However, should
they occur, they will be recorded in keeping with routine
clinical practice.
Ethics and dissemination
Ethics approval and consent
The study will be conducted in accordance with the
principles of Good Clinical Practice. Approval was ob-
tained from the East of Scotland Ethics Committee (ap-
proval number: 09/S1401/56) and National Health Service
Tayside Research and Development (approval number:
20092E07). Any changes in research activity, except those
necessary to remove an apparent, immediate hazard to the
participant, will be reviewed and approved by one of the
co-chief investigators. Amendments to the protocol will
be submitted in writing to the East of Scotland Ethics
Committee and Tayside National Health Service Research
and Development.
Informed consent will be taken by the treating clinician
(member of the research team) after clarifying any queries
asked by the patient and/or the parents. In all trial sites,
one of the trial team who is suitably trained will obtain
consent from the participant and/or parent(s) or legal
guardian(s). All research team clinicians will have had pre-
vious Good Clinical Practice training including obtaining
informed consent. An independent clinician who is not
part of the trial research group agreed to be an independ-
ent reference for participants and parents in case there are
any further queries regarding the study. His contact infor-
mation is included in the participant information sheet.
The participant and/or parent(s)/legal guardian(s) in
the study will provide written informed consent before
any study procedures are carried out and a participant
information sheet will be provided to facilitate this
process. Those with English as an additional language will
be invited to bring an interpreter with them to the subse-
quent treatment appointment, or to request an NHS inter-
preter, where this service is available. As part of the
consent process participants and/or parent(s)/legal guard-
ian(s) must agree to researchers and regulatory rep-
resentatives having access to their medical records for
monitoring and audit purposes. Participants and/or
parent(s)/legal guardian(s) may withdraw their consent
to participate at any time during the study. The inves-
tigator or delegated member of the trial team and the
child should sign and date the assent form whereas the
participant (and/or parent(s)/legal guardian(s)) and investiga-
tor should sign the informed consent form(s) to confirm that
consent has been obtained. The participant should then
receive a copy of this document and a copy should be filed
in the investigator site file. Patients who refuse to enter
the trial will also be recorded. Their demographic and
clinical details will be compared at the end of the study to
determine that volunteer bias was not present.
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Withdrawal procedures
Parent(s)/legal guardian(s) will be informed that they
have the right to withdraw from the study at any time.
The right to refuse to participate without reasons will be
respected. After the participant has entered the study
the clinician remains free to provide alternative treat-
ment to that specified in the protocol at any stage if he/
she feels that it is in the participant’s best interest, but
the reasons for doing so will be recorded. In these cases
the participants remain within the study for the purposes
of follow-up and data analysis. All participants will be free
to withdraw at any time from the study without giving rea-
sons and without prejudicing further treatment.
Confidentiality
All participants’ records will be identified in a manner de-
signed to maintain participant confidentiality. All records
will be kept in a secure storage area with limited access.
Clinical information will not be released without the writ-
ten permission of the participant, except as necessary for
monitoring and auditing by the sponsor, its designee, regu-
latory authorities or the REC. All investigators and study
site staff involved with this study will comply with the re-
quirements of the Data Protection Act (UK) 1998 with re-
gard to the collection, storage, processing and disclosure
of personal information and will uphold the Act’s core
principles. Computers used to gather the data will have
limited access via user names and passwords. Published
results will not contain any personal data that could allow
the identification of participants.
Dissemination of results and publication policy
The ownership of the data from the current trial resides
with the trial team. On competition of the trial the data
will be analyzed and a clinical study report will be pre-
pared. In addition, the results of the trial will be presented
at orthodontic national and international conferences and
meetings. All patients recruited in the trial will be given a
summary of the findings after the final report is finalized.
Discussion
Orthodontic treatment with fixed appliances usually
takes around two years to complete. Therefore this ran-
domized controlled trial presents potential difficulties
with participant dropout due to patients moving to other
treatment centers and clinicians failing to obtain treat-
ment records at key stages during treatment. Although it
is not possible to prevent the former, the latter source of
bias will be minimized by regular trial updates and re-
minders throughout the duration of the trial.
The results from the current study will serve as evi-
dence to guide clinicians in deciding whether the differ-
ence in bracket slot size has a significant impact on the
effectiveness of orthodontic treatment.
Trial status
The current trial is open for recruitment since January
2010 and is expected to reach the target enrolment of
216 participants in September 2014.
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